Neuroleptic malignant syndrome in elderly patients

References

• Delay J, Pichot P, Lemperiere T, Elissade B, Peigne F. Un neuroleptique majeur non-phenothiazine et non reserpinique, l’haloperidol, dans le traitement des psychoses. Ann. Med. Psychol. (Paris)118, 145–152 (1960).
   PubMedGoogle Scholar
• Caroff SN. The neuroleptic malignant syndrome. J. Clin. Psychiatry41, 79–83 (1980).
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med. Clin. North America77, 185–202 (1993).
   PubMed Web of Science ®Google Scholar
• Caroff SN. Neuroleptic malignant syndrome. In: Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition. Mann SC, Caroff SN, Lazarus A, Keck PE Jr (Eds). American Psychiatric Press Inc., Washington, DC, USA 1–41 (2003).
   Google Scholar
• Spivak B, Maline DI, Kozyrev VN et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur. Psychiatry15, 330–333 (2000).
   PubMed Web of Science ®Google Scholar
• Stubner S, Rustenbeck E, Grohmann R et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry37, S54–S64 (2004).
   Google Scholar
• Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch. Gen. Psychiatry46, 914–918 (1989).
   PubMed Web of Science ®Google Scholar
• Berardi D, Amore M, Keck PE Jr, Troia M, Dell’Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case control study. Biol. Psychiatry44, 748–754 (1998).
   PubMed Web of Science ®Google Scholar
• Caroff SN, Rosenberg H, Mann SC, Campbell EC, Gliatto MF, Sullivan KA. Neuroleptic malignant syndrome in the perioperative setting. Am. J. Anesthesiol.28, 387–393 (2001).
   Google Scholar
• White DAC, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Brit. J. Psychiatry158, 419–421 (1991).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat. Disord.9, S3–S9 (2003).
   PubMedGoogle Scholar
• Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr. Ann.30, 314–321 (2000).
   Web of Science ®Google Scholar
• Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J. Nerv. Ment. Dis.182, 168–173 (1994).
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol. Bull.24, 25–29 (1988).
   PubMedGoogle Scholar
• Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J. Clin. Psychopharmacol.20, 257–259 (2000).
   PubMed Web of Science ®Google Scholar
• Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr. Ann.30, 325–331 (2000).
   Web of Science ®Google Scholar
• Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol. Psychiatry44, 378–381 (1998).
   PubMed Web of Science ®Google Scholar
• Caroff SN, Mann SC, Gliatto MF, Sullivan KA, Campbell EC. Psychiatric manifestations of acute viral encephalitis. Psychiatr. Ann.31, 193–204 (2001).
   Web of Science ®Google Scholar
• Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J. Clin. Psychopharmacol.18, 349–351 (1998).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N. Engl. J. Med.355, 1525–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Goveas JS, Caroff SN, Riggio S. Beware ictal activity that mimics psychiatric illness. Curr. Psychiatry5, 69–86 (2006).
   Google Scholar
• Factor SA, Santiago A. Parkinsonism – hyperpyrexia syndrome in Parkinson’s disease. In: Movement Disorder Emergencies: Diagnosis and Treatment. Frucht SJ, Fahn S (Eds). Humana Press, NJ, USA 29–40 (2005).
   Google Scholar
• McKeith IG, Perry RH, Fairbairn AF et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol. Med.22, 911–922 (1992).
   PubMed Web of Science ®Google Scholar
• Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am. J. Psychiatry143, 1374–1381 (1986).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Arnold LM. The serotonin syndrome. Psychiatr. Ann.30, 333–343 (2000).
   Web of Science ®Google Scholar
• Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting. Ann. Clin. Psychiatry18, 201–204 (2006).
   PubMedGoogle Scholar
• Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of the neuroleptic malignant syndrome. Psychiatr. Ann.30, 363–374 (2000).
   Web of Science ®Google Scholar